Exisulind
| Chemical Compound | |
|---|---|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider ID | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Properties | |
| Chemical Formula | |
| Molar Mass | |
| Appearance | |
| Density | |
| Melting Point | |
| Boiling Point | |
| Hazards | |
| GHS Pictograms | [[File:|50px]] |
| GHS Signal Word | |
| GHS Hazard Statements | |
| NFPA 704 | [[File:|50px]] |
| References | |
Exisulind (tentative trade name Aptosyn) is an antineoplastic agent. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase type 5 (EC 3.1.4.17 ).[1] It is the sulfone derivative of sulindac, an NSAID. Unlike sulindac, it has known effects on prostaglandin synthesis.[2] It was developed as the potential treatment of several conditions including familial adenomatous polyposis (FAP), precancerous sporadic colonic polyps, cervical dysplasia and the prevention of tumor recurrence in prostate and breast cancer.[3] Exisulind inhibits the enzyme cGMP-PDE, overexpressed in precancerous and cancerous colorectal cells, and induces apoptosis in such cells with minimal effects on normal cells. This apoptotic effect is independent of COX-1 or COX-2 inhibition, p53, Bcl-2, or cell cycle arrest. Preclinical evidence suggests that exisulind also inhibits angiogenesis.[4]
See also
References
- ↑ , Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone., Drugs in R&D, Vol. 5(Issue: 4), pp. 220–6, PMID: 15230629,
- ↑ , Phase I trial of Exisulind (Sulindac Sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis., Clinical Cancer Research, Vol. 6(Issue: 1), pp. 78–89, PMID: 10656435,
- ↑ , Exisulind Cell Pathways., Current Opinion in Investigational Drugs, Vol. 1(Issue: 3), pp. 386–91, PMID: 11249724,
- ↑ , Inhibition of Angiogenesis by Sulindac and its Sulfone Metabolite (FGN-1): a Potential Mechanism for Their Antineoplastic Properties., International Journal of Tissue Reactions, Vol. 20(Issue: 3), pp. 85–9, PMID: 9894180,
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
